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disorder
Abstract
Background: It is often suggested in the literature that alexithymic patients are less responsive to
psychotherapy than nonalexithymic patients. However, few empirical studies have examined this issue.
Furthermore, it is unclear whether or not alexithymia itself may improve during psychotherapy.
Methods: Fifty-five consecutive outpatients with panic disorder received short-term
cognitive-behavioral group therapy (CBGT) and were followed up 6 months later. Nineteen patients
(35%) were on concomitant antidepressant medication. Alexithymia was measured using the 20-item
Toronto Alexithymia Scale (TAS-20). Both completers and intention-to-treat analyses were calculated,
taking into consideration the potentially confounding effect of comorbid conditions. Results: Baseline
alexithymia did not predict outcome of CBGT, neither at posttreatment nor at follow-up. The presence
of comorbid axis I disorders predicted nonresponse at posttreatment but not at follow-up. TAS-20 total
scores decreased over time, with the TAS-20 factors 1 (difficulty identifying feelings) and 2 (difficulty
describing feelings) decreasing significantly, while factor 3 (externally oriented thinking) remained
largely stable. Conclusions: These findings are encouraging for cognitive-behavioral therapists working
with patients with alexithymia who suffer from panic disorder: CBGT outcome does not appear to be
negatively affected by alexithymia, and some alexithymic characteristics may even be reduced
following CBGT. Assessing alexithymia at treatment onset may be useful for individually tailoring
therapeutic interventions.
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creasing significantly, while factor 3 (externally oriented 
thinking) remained largely stable.  Conclusions: These find-
ings are encouraging for cognitive-behavioral therapists 
working with patients with alexithymia who suffer from pan-
ic disorder: CBGT outcome does not appear to be negatively 
affected by alexithymia, and some alexithymic characteris-
tics may even be reduced following CBGT. Assessing alexi-
thymia at treatment onset may be useful for individually tai-
loring therapeutic interventions. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Alexithymia as a construct refers to deficits in the reg-
ulation of emotions  [1–3] . It is related to a variety of phys-
ical and mental health problems  [3, 4] . The typical fea-
tures of alexithymia include difficulties in identifying 
and describing feelings, difficulties in differentiating be-
tween emotional states and physical sensations, a con-
stricted imaginative activity, and an externally oriented 
cognitive style  [1, 5] . Similarly, individuals with high anx-
iety sensitivity also show a proneness to focus on bodily 
sensations, based on their alertness to anxiety-related 
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ithymic patients are less responsive to psychotherapy than 
nonalexithymic patients. However, few empirical studies 
have examined this issue. Furthermore, it is unclear whether 
or not alexithymia itself may improve during psychotherapy. 
 Methods: Fifty-five consecutive outpatients with panic dis-
order received short-term cognitive-behavioral group ther-
apy (CBGT) and were followed up 6 months later. Nineteen 
patients (35%) were on concomitant antidepressant medica-
tion. Alexithymia was measured using the 20-item Toronto 
Alexithymia Scale (TAS-20). Both completers and intention-
to-treat analyses were calculated, taking into consideration 
the potentially confounding effect of comorbid conditions. 
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CBGT, neither at posttreatment nor at follow-up. The pres-
ence of comorbid axis I disorders predicted nonresponse at 
posttreatment but not at follow-up. TAS-20 total scores de-
creased over time, with the TAS-20 factors 1 (difficulty iden-
tifying feelings) and 2 (difficulty describing feelings) de-
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stimuli  [6] . Empirically, there is evidence for a close rela-
tion between alexithymia and anxiety sensitivity  [6–8] .
 Many patients with panic disorder (PD), which is as-
sociated with anxiety sensitivity  [8] , show disturbances 
in emotion regulation, have the tendency to misinterpret 
nonthreatening sensations of autonomic arousal as symp-
toms of bodily diseases, and are unable to relate such 
symptoms to psychological factors. Thus, a strong asso-
ciation of PD with alexithymia was hypothesized and 
empirically confirmed  [8–15] . The prevalence of alexi-
thymia in patients with PD was estimated in the range of 
29–58% [e.g.,  11, 15 ].
 Alexithymia has also been shown to negatively influ-
ence treatment outcome in various conditions such as 
posttraumatic stress disorder  [16] , functional gastroin-
testinal disorders  [17] , and eating disorders  [18] . None of 
these studies, however, specifically investigated the im-
pact of alexithymia on the outcome of psychotherapy, al-
though it has been suggested that alexithymic patients 
are less responsive to psychotherapy  [19] . This view is 
mainly based on clinical experiences and theoretical as-
sumptions. Proposed explanations include the difficulty 
of alexithymic patients to elaborate their emotions, their 
little interest in introspective and analytical cognitive ac-
tivity, and their capacity to trigger negative therapist re-
actions  [18, 20–22] . As a consequence, some authors rec-
ommended a supportive rather than change-oriented 
psychotherapeutic approach to alexithymic patients  [23, 
24] . Thus, the question of whether or not alexithymia pre-
dicts psychotherapy outcome is highly clinically relevant. 
Despite this, relatively few studies empirically investi-
gated  the  role  of  alexithymia in predicting psychother-
apy outcome. We electronically searched PubMed and 
PsycINFO databases for articles on this topic. The search 
terms ‘alexithymia’, ‘psychotherapy’, and ‘outcome’ were 
used, and additional articles were obtained from refer-
ence list searches. Summarizing these studies, there 
seems to be increasing evidence supporting the view that 
alexithymic patients respond poorly to psychodynamic 
psychotherapy ( table 1 ). Although it has been suggested 
that alexithymia has a less negative impact on the out-
come of cognitive-behavioral therapy (CBT) as compared 
to psychodynamic treatment  [25] , very few studies exam-
ined the predictive value of alexithymia for the outcome 
of CBT, yielding inconsistent results ( table 2 ).
 We therefore conducted a prospective study of outpa-
tients who received CBT for PD (including exposure ther-
apy), and evaluated (1) the predictive value of alexithymia 
for the outcome of CBT, taking into specific consider-
ation the possible confounding effects of comorbid de-
pressive symptoms, and (2) the degree to which alexi-
thymia can change over time. Based on the results of pre-
vious studies on CBT for obsessive-compulsive disorder 
 [26, 27] , we hypothesized that (1) the outcome would not 
be negatively affected by alexithymia, and (2) CBT with 
exposure therapy, during which patients were asked to 
describe precisely the intensity and the different qualities 
of their emotions, would go along with improvements in 
the typical feature of alexithymia ‘difficulties in identify-
ing and describing feelings’.
 Method 
 Patients 
 The study was approved by the ethics committee of the Ärz-
tekammer Hamburg, Germany. Patients were consecutively re-
cruited between February 2004 and October 2005 from the Be-
haviour Therapy Outpatient Unit of the Department of Psychia-
try and Psychotherapy (University Hospital of Hamburg, 
Germany). To be included in the study, patients had to be diag-
nosed by an experienced clinician with the primary diagnosis of 
PD with or without agoraphobia and to score 7 or higher on the 
clinician-rated version of the Panic and Agoraphobia Scale (PAS), 
an empirically derived cutoff indicating at least mild symptom 
severity  [28] . The Mini-International Neuropsychiatric Interview 
 [29] for DSM-IV [German version: 30 ], a reliable and valid, struc-
tured diagnostic interview, was used to confirm the diagnosis of 
PD with or without agoraphobia and to establish comorbid diag-
noses. Exclusion criteria were current or past psychotic disorders, 
organic mental disorders, current substance dependence, and an 
acute risk of suicide (as assessed by an experienced clinician). All 
other comorbid disorders were allowed as we intended to evaluate 
a clinically representative sample of PD outpatients.
 A total of 55 consecutive patients were eligible for this study, 
none of whom refused to participate. Written informed consent 
was obtained from all patients prior to study enrollment. Thirty-
two (58%) out of 55 patients had a diagnosis of PD without agora-
phobia, 23 patients (42%) PD with agoraphobia. These subgroups 
were not analyzed separately because of the small sample size. 
One or two comorbid axis I disorders were diagnosed in 22 pa-
tients (40%). The most frequent diagnosis was major depression 
(n = 15, 28%); others were obsessive-compulsive disorder (n = 4), 
dysthymia (n = 3), social phobia (n = 2), anorexia nervosa (n = 1), 
alcohol abuse (n = 1), and generalized anxiety disorder (n = 1).
 Posttreatment data were provided by 50 patients (91%). Non-
completers either finished treatment but refused to participate in 
posttreatment assessment (3 patients) or dropped out of treat-
ment due to noncompliance (2 patients, both after the second ses-
sion). The latter were reassessed after they dropped out; these data 
were used for intention-to-treat analyses (see ‘statistical analy-
ses’). Six months after the end of therapy, all treatment completers 
were asked to participate in a follow-up assessment. Those who 
refused to come for a face-to-face interview were offered an inter-
view by telephone. Forty-three patients (78% of all originally en-
rolled in the study) participated in the 6-month follow-up (36 by 
face-to-face interview and 7 by telephone) while the remaining 7 
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patients could not be traced or refused to participate. Compari-
sons of treatment completers with noncompleters and follow-up 
completers with noncompleters showed no significant differences 
in gender, age, pretreatment scores of PAS, 20-item Toronto Alex-
ithymia Scale (TAS-20), and Beck Depression Inventory (BDI) 
(data not shown, all p  1 0.19).
 Treatment 
 All patients were treated with short-term cognitive-behavior-
al group therapy (CBGT) for PD. Each group comprised 5–7 pa-
tients, and treatment was conducted by 2 psychotherapists. Ther-
apists were either licensed cognitive-behavioral therapists, skilled 
and experienced in treating patients with anxiety disorders, or 
Table 1. Empirical studies on the predictive value of alexithymia for the outcome of psychodynamic therapy
Study n Diagnoses Assessment
of alexithy-
mia
Therapy approach Mean duration 
of therapy 
(weeks)
Assessment
of outcome
Time point
of outcome 
assessment
Results
McCallum
et al. [61]
251 Complicated grief 
and different axis
I and II disorders
TAS-20 (1) Interpretive 
outpatient therapy 
(individual and group 
therapy)
(2) Supportive outpatient 
therapy (individual and 
group therapy)
(1) 12
(2) 20
Different 
scales, 
including 
TRIG
Post-
treatment
Alexithymia predicted 
poor outcome in all 
treatment groups
Ogrodniczuk
et al. [62]
33 Major depression 
(subsample of Ref. 
61; all patients were 
therapy responders)
TAS-20 Interpretive and
supportive individual 
outpatient therapy
20 BDI Post-
treatment
Difficulty in identifying 
feelings predicted the 
persistence of depressive 
residual symptoms
Ogrodniczuk
et al. [21]
107 Complicated grief 
and different axis
I and II disorders 
(subsample of Ref. 
61)
TAS-20 Interpretive outpatient 
therapy (individual and 
group therapy)
12 Different 
scales, 
including 
TRIG
Post-
treatment
Alexithymia predicted 
poor treatment outcome
Spitzer
et al. [63]
149 Different axis I 
and II disorders
TAS-20 Psychodynamic
inpatient therapy
Not available IIP Post-
treatment
Alexithymia did not 
predict changes in 
interpersonal problems, 
but high-alexithymic 
patients had still more 
interpersonal problems 
at the end of treatment 
than low-alexithymic 
patients
Simson
et al. [64]
48 Different axis I 
and II disorders
LEAS;
TAS-20
Psychodynamic
inpatient therapy
8.5 GAF Post-
treatment
High scores in emotional 
awareness (LEAS) 
predicted good treatment 
outcome, but TAS-20 
scores were not 
associated with the 
treatment outcome
Grabe
et al. [65]
297 Different axis I 
and II disorders 
TAS-20 Psychodynamic
inpatient therapy
8–12 GSI of 
SCL-90-R
Post-
treatment
Alexithymia did not 
predict poor treatment 
outcome, but alexithymic 
patients suffered more 
from psychopathological 
distress at discharge than 
nonalexithymic patients
Leweke
et al. [66]
480 Different axis I
disorders
TAS-26 Psychodynamic
inpatient therapy
Short-term 
(limited to 4 
weeks) and long-
term therapy 
(8–12 weeks)
GSI and 
depression 
subscale
of SCL-90-R
Post-
treatment
Alexithymia predicted 
less favorable outcome, 
especially in patients 
with somatoform 
disorders
TRIG = Texas Revised Inventory of Grief; IIP = Inventory of Interpersonal Problems; LEAS = Levels of Emotional Awareness Scale; GAF = Glo-
bal Assessment Scale of Function; GSI = Global Severity Index.
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had reached an advanced level in their CBT training. They all re-
ceived supervision on a weekly basis.
 The fully manualized CBGT protocol  [31] consisted of 5 week-
ly sessions of 150 min each (including a 15-min break). Sessions 1 
and 2 included psychoeducation about normal anxiety, anxiety 
disorders, coping strategies, and the treatment of anxiety disor-
ders. The therapists presented and discussed a cognitive-behav-
ioral model of panic attacks (‘vicious circle of anxiety’), the rela-
tionship of stress and anxiety, and emphasized the role of avoid-
ance in maintaining anxiety. Both sessions finished with 20 min 
training in progressive muscle relaxation skills. As part of their 
assigned homework, patients were asked to self-monitor their 
symptoms and thoughts before, during and after panic attacks. In 
addition, they were required to practice relaxation at least once 
daily.
 At the beginning of each therapy session, patients were asked 
about their success and possible difficulties with their assigned 
homework. From our clinical observation, the great majority of 
patients completed most of their homework. As pointed out by 
Lumley et al. [25] , the compulsive nature and external focus of 
people with alexithymia possibly prompt good adherence to 
structured exercises and behavioral recommendations. However, 
the adherence to homework was not formally assessed in our 
study.
 Session 3 focused on therapist-guided exposure to panic-like 
physical sensations by running up a flight of stairs to get patients’ 
hearts racing. Therapists used patients’ reports of symptoms of 
anxiety elicited during exposure to teach management of anxiety 
and other negative emotional states, in order to improve their 
ability to cope with distressing emotions  [32] . Patients were en-
couraged to describe precisely the intensity and the different 
qualities  of  their  emotions.  In  addition,  therapists  asked them 
for their accompanying cognitions. For example, when patients 
judged their physical sensations as dangerous, they were asked to 
evaluate the validity of their catastrophic thoughts and to try to 
change them into more rational ones. At the end of the session, 
patients compared their new experiences with their earlier expec-
tations (cognitive restructuring). They were also asked to do self-
exposure homework and apply the coping strategies learned dur-
ing therapy. Sessions 4 and 5 focused on cognitive restructuring 
with an emphasis on the evaluation of patients’ self-exposure ex-
periences and their individual beliefs and appraisals. The therapy 
finished with the discussion of relapse prevention strategies [for 
a more detailed description of the CBGT protocol, see the treat-
ment manual,  31 ]. A recent study showed that quality of life of 
patients with PD improved following this short-term group ther-
apy program  [33] .
 Patients were allowed to continue psychopharmacological 
medication taken before entering the study if this therapeutic reg-
imen had remained stable for at least 2 weeks prior to the first 
CBGT session. Nineteen patients (35%) received concomitant 
medication. Sixteen patients were treated with either a selective 
serotonin reuptake inhibitor (SSRI) or a tricyclic antidepressant, 
2 patients with low-dose benzodiazepines, and 1 patient with two 
different antidepressants in combination with a low-dose ben-
zodiazepine. Nearly all patients kept their medication stable 
throughout the group therapy; only 2 patients switched to anoth-
er antidepressant and 3 patients stopped medication. None of the 
patients started new medication during group therapy. There 
were also relatively few medication changes during the 6-month 
follow-up period. Four patients started antidepressant medica-
tion, 1 patient added an SSRI to the existing tricyclic antidepres-
sant medication, and another patient added a low-dose benzodi-
azepine to the existing SSRI medication.
Table 2. Empirical studies on the predictive value of alexithymia for the outcome of cognitive-behavioral therapy
Study n Diagnoses Assessment
of alexithy-
mia
Therapy approach Mean 
duration of 
therapy 
weeks
Assessment
of outcome
Time point
of outcome
assessment
Results
Bach and 
Bach [50]
30 Panic disorder or 
somatoform disorder
TAS-26 Inpatient cognitive 
behavioral therapy
>8 SCL-90-R 2-year FU Alexithymia predicted 
poor treatment outcome
Rufer
et al. [26, 27]
42 Obsessive-compul-
sive disorder
TAS-20 Inpatient cognitive 
behavioral therapy
10 Y-BOCS Posttreatment 
and 6-year FU
No association of 
alexithymia with outcome, 
neither at posttreatment 
nor at FU
Rosenblum
et al. [67]
230 Alcohol and drug
abuse
TAS-20 (1) Outpatient 
cognitive behavioral 
group therapy
(2) Outpatient 
group motivational 
intervention
10 Time of 
abstinence 
from alcohol 
and drugs
15-week FU Patients with more severe 
alexithymia derived 
greater benefit from 
cognitive behavioral 
therapy than from 
motivational intervention 
program
Spek
et al. [68]
201 Subthreshold 
depression
TAS-20 Cognitive behavioral 
therapy
Not
available
BDI Posttreatment 
and 1-year FU
Baseline alexithymia 
scores were not correlated 
with treatment outcome
FU = Follow-up; Y-BOCS = Yale-Brown Obsessive-Compulsive Scale.
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 None of the patients received additional psychotherapy during 
the CBGT period (ongoing psychotherapies were discontinued 
before CBGT started). At follow-up, 11 patients were receiving 
individual psychotherapy.
 Measures 
 Experienced and specifically trained, independent interview-
ers who were not involved in the treatment process conducted all 
clinician ratings. A given patient was always assessed by the same 
interviewer. Alexithymia was evaluated with the German version 
 [34] of the TAS-20  [35] , a reliable and valid self-rating measure of 
the alexithymia construct. Empirically validated, this instrument 
contains the following factors: difficulty identifying feelings (fac-
tor 1), difficulty describing feelings (factor 2), and externally ori-
ented thinking (factor 3). The TAS-20 is the most widely used 
measure of alexithymia, and the generalizability of its 3-factor 
structure was demonstrated across languages and cultures, in-
cluding the German version used in the present study  [36] .
 The clinician-rated version of the PAS [ 37 , German version: 
 38 ] was used as the main outcome measure, together with the cli-
nician-rated version of the global improvement item (ranging 
from 1 = ‘very much improved’ to 7 = ‘very much worse’) of the 
Clinical Global Impression Scale (CGI) [ 39 , German version:  40 ]. 
The PAS contains 13 items with Likert-type scales (from 0 to 4). 
The scale was validated on a cross section of 452 patients with PD 
 [38] . In addition, previous studies demonstrated that the PAS is 
appropriate for use in a variety of clinical and research environ-
ments and, because of its sensitivity to changes over time, it is a 
useful tool for assessing treatment efficacy in PD trials  [37, 41, 42] . 
Secondary outcome measures were the Hamilton Anxiety Rating 
Scale (HARS) [ 43 , German version:  40 ] and the Global Severity 
Index of the Symptom Checklist-90-Revised (SCL-90-R) [ 44 , 
German version:  45 ]. Symptoms of depression were assessed with 
the BDI [ 46 , German version:  47 ].
 Statistical Analyses 
 For between-group comparisons, we used   2 tests for categor-
ical variables and t tests for continuous variables. The scores of 
the TAS-20, PAS, HARS, SCL-90-R, and BDI were submitted to 
analyses of variance (ANOVAs) with repeated measures (pre-
treatment, posttreatment, and follow-up). When the sphericity 
assumption was violated, p values were Greenhouse-Geisser cor-
rected. Effect sizes were estimated using partial effect sizes   2. 
According to Cohen  [48] ,   2 values of 0.0099, 0.0588 and 0.1379 
correspond to small, medium and large effect sizes, respectively. 
We did not use the international threshold criterion for alexi-
thymia (TAS-20  6 61) because of the small sample size and since 
this cutoff criterion may not be representative for the German 
population  [49] . Since high test-retest correlations of the TAS-20 
would underline the usefulness of this variable as a potential pre-
dictor  [18] , we calculated Pearson correlations, intraclass correla-
tions and Cronbach’s   . Regression analyses were performed to 
evaluate the predictive value of alexithymia for the posttreatment 
and follow-up outcome of CBGT. For all analyses of treatment 
outcome, both completers and intention-to-treat analyses (carry-
ing the last observation forward) were calculated. In all analyses, 
the level of significance was set at p  ! 0.05 (two-sided). The Sta-
tistical Package for Social Sciences, version 12.0.1 (SPSS, Chicago, 
Ill., USA) was used for all calculations.
 Results 
 Pretreatment Characteristics and Their Relationship 
with Alexithymia 
 At pretreatment, patients had a mean PAS score of 21.4 
( 8 7.8), indicating moderate severity of PD symptoms. 
Further clinical and demographical characteristics are 
listed in  table 3 . Alexithymia did not correlate signifi-
cantly with age (r = –0.19, nonsignificant) and duration 
of illness (r = –0.13, nonsignificant), and there were no 
significant differences in alexithymia scores between 
men and women (t = 0.74, d.f. = 53, nonsignificant). A 
significant positive correlation was found between alexi-
thymia and BDI depression scores (r = 0.30, p  ! 0.05) but 
not between alexithymia and PAS scores (r = 0.22, non-
significant).
 Change in Anxiety and Depression over Time 
 In the group of follow-up completers (n = 43), the re-
peated measure ANOVA showed a significant PAS re-
duction from 21.1 ( 8 8.0) at pretreatment to 14.6 ( 8 9.7) 
at posttreatment and 11.5 ( 8 10.5) at follow-up [F (2,84) = 
30.31, p  ! 0.001] with a large effect size (  2 = 0.42). Post 
hoc analyses revealed significant differences from both 
Table 3. Pretreatment demographic and clinical characteristics of 
55 patients with PD
Mean SD
Age, years 39.7 11.3
Illness duration, years 3.5 5.0
TAS-20 total score 50.0 9.6
Factor 1 (difficulty in identifying feelings) 18.0 6.0
Factor 2 (difficulty in describing feelings) 12.9 3.3
Factor 3 (externally oriented thinking) 19.2 3.9
PAS 21.4 7.8
HARS 20.0 9.0
BDI 14.5 8.7
SCL-90-R GSI 0.9 0.6
Patients
n %
Gender, female/male 34/21 61.8/38.2
Married/not married (or cohabiting) 44/11 80.0/20.0
Education level
No secondary school degree (<10 years) 13 23.6
Secondary school degree (10 years) 12 21.8
High-school diploma (13 years) 19 34.5
University degree 11 20.0
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pre- to posttreatment (t = 5.98, d.f. = 42, p  ! 0.001) and 
posttreatment to follow-up (t = 2.41, d.f. = 42, p = 0.02). 
BDI scores also improved significantly, with a medium to 
large effect size (  2 = 0.14), from pretreatment (14.0  8 
7.8) to posttreatment (12.6  8 10.2) and follow-up (10.9  8 
9.1) [F (2,84) = 6.23, p = 0.003]. Post hoc analyses showed 
a trend toward reduction from pre- to posttreatment (t = 
1.88, d.f. = 42, p = 0.07) and posttreatment to follow-up 
(t = 1.69, d.f. = 42, p = 0.098). Similarly, the secondary 
outcome measures were significantly reduced over time: 
HARS: F (2,84) = 14.46, p  ! 0.001; SCL-90-R: GSI F (2,84) 
= 14.26, p  ! 0.001. Repeating all ANOVAs with missing 
data being imputed by carrying the last observation for-
ward did not substantially change these results (all p  ! 
0.006).
 Change in Alexithymia over Time 
 Results presented in  table 4 show a significant decrease 
in alexithymia total scores over time. The significant pos-
itive correlation between alexithymia and depression at 
pretreatment suggested that improvements in alexi-
thymia might be at least partly explained by improve-
ments in depression. Therefore, we controlled for the po-
tential influence of depression by using a linear mixed 
model with repeated-measures covariates. Following this 
procedure, improvement of alexithymia over time re-
mained significant [F (2,61.8) = 3.98, p = 0.024]. A closer 
examination on the TAS-20 factor level showed that the 
decrease in alexithymia total scores was mainly due to 
changes in factor 1 (difficulty identifying feelings) and 
factor 2 (difficulty describing feelings), whereas factor 3 
(externally oriented thinking) remained almost com-
pletely stable over time ( table 4 ).
 To examine the relative stability of alexithymia, we 
correlated TAS-20 scores both between pre- and post-
treatment and between posttreatment and follow-up. As 
shown in  table 5 , the test-retest reliability was high for 
both time periods.
 Predictive Value of Alexithymia for Outcome 
 Two different outcome criteria were defined: (1) focus-
ing on the panic and agoraphobia symptoms, outcome 
Table 4. Changes of alexithymia scores from pre- to posttreatment and to 6-month follow-up (n = 43)
Pretreatment Posttreatment Follow-up ANOVAs (d.f. = 2)
F p effect size 2
TAS-20 total score 49.2 (9.7) 47.1 (10.3) 44.2 (11.2) F (84) = 9.18 0.001a 0.18
Factor 1 17.7 (6.0) 16.5 (5.1) 15.0 (5.8) F (84) = 5.64 0.012b 0.12
Factor 2 12.7 (3.0) 11.8 (3.7) 10.8 (3.8) F (84) = 7.50 0.001c 0.15
Factor 3 18.8 (4.0) 18.8 (4.2) 18.4 (4.5) F (84) = 0.31 0.740 0.01
ANOVAs = Analyses of variance (all p values Greenhouse-Geisser corrected).
a Pre and post comparison: t = 2.3, d.f. = 42, p = 0.03; post and follow-up comparison: t = 2.55, d.f. = 42, p = 0.02.
b Pre and post comparison: t = 2.09, d.f. = 42, p = 0.04; post and follow-up comparison: t = 2.96, d.f. = 42, p = 0.05.
c Pre and post comparison: t = 1.83, d.f. = 42, p = 0.08; post and follow-up comparison: t = 2.18, d.f. = 42, p = 0.04.
Table 5. Correlations between alexithymia scores at pretreatment, posttreatment and 6-month follow-up
Pre- to posttreatment (n = 50) Posttreatment to follow-up (n = 43)
Pearson’s r ICC r Cronbach’s  Pearson’s r ICC r Cronbach’s 
TAS-20 total score 0.77** 0.75** 0.87 0.77** 0.74** 0.87
Factor 1 0.78** 0.75** 0.87 0.61** 0.58** 0.75
Factor 2 0.57** 0.55** 0.72 0.67** 0.64** 0.80
Factor 3 0.64** 0.63** 0.77 0.62** 0.62** 0.76
** p < 0.001. ICC = Intraclass correlation coefficient. 
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was defined as posttreatment PAS scores and follow-up 
PAS scores, respectively (controlled for baseline PAS 
scores) and (2) focusing on the global improvement, re-
sponse to therapy was defined as CGI score of 1 or 2 (very 
much improved or much improved) at posttreatment and 
follow-up, respectively. Thus, according to the CGI, 25 
out of 50 treatment completers (50%) were categorized as 
responders at posttreatment, while 19 of the 43 follow-up 
completers (44%) were rated as responders at follow-up.
 Stepwise regression analyses were performed with the 
two outcome criteria as dependent, and pretreatment 
TAS-20 total scores as independent variables. The follow-
ing pretreatment variables were also included as indepen-
dent variables because of their potential impact on the 
therapy outcome: BDI scores, concomitant medication 
during therapy (0 = no medication; 1 = with medication), 
and the presence of comorbid axis I disorders (without 
comorbid disorder = 0; with comorbid disorder = 1).
 Regarding the first outcome criterion (PAS scores), 
linear regression analyses were performed. Baseline PAS 
scores were first entered to control for baseline severity. 
The analyses revealed that alexithymia was neither re-
lated to the posttreatment nor to the follow-up outcome. 
Except for baseline PAS scores (p  ! 0.001, for both post-
treatment and follow-up outcome), none of the indepen-
dent variables reached significance and entered into the 
equation. Imputing missing data using the last-observa-
tion-carried-forward method did not change these re-
sults.
 Regarding the second outcome criterion (CGI scores), 
logistic regression analyses for the posttreatment re-
sponse revealed that the presence of a comorbid axis I 
disorder significantly predicted nonresponse to therapy 
(R 2 = 0.11,   = –1.2, p = 0.04). Neither alexithymia nor the 
other independent variables entered into the equation. 
None of the variables significantly predicted response at 
follow-up.
 Discussion 
 The main aims of the present study were to evaluate 
(1) the predictive value of alexithymia for the outcome of 
CBGT for PD and (2) the degree to which alexithymia can 
change over time. The results showed (1) no significant 
impact of alexithymia on the posttreatment or follow-up 
outcome following CBGT and (2) a decrease in alexi-
thymia over time, even after controlling for depression. 
This decrease was mainly attributable to changes in TAS-
20 factors 1 (difficulty identifying feelings) and 2 (diffi-
culty describing feelings), indicating that patients im-
proved their ability to recognize their feelings and com-
municate them to others, while factor 3 (externally 
oriented thinking) remained largely stable.
 Our finding that baseline alexithymia did not predict 
outcome of CBGT is in accordance with a study of pa-
tients with obsessive-compulsive disorder, showing that 
alexithymia, as measured with the TAS-20, had no nega-
tive impact on the outcome of CBT at posttreatment  [26] 
and at 6-year follow-up  [27] . In contrast, in a sample of 
inpatients suffering from somatoform disorder and PD, 
alexithymia, as assessed with the TAS-26, predicted per-
sistent somatization following multimodal CBT  [50] . 
This study, however, suffered from a number of method-
ological shortcomings, including the lack of symptom as-
sessment immediately after treatment. Thus, there seems 
to be increasing evidence suggesting that alexithymia has 
no negative impact on the outcome of CBT. This seems to 
be understandable because CBT does not primarily focus 
on insight, nor exclusively on verbal interventions, but on 
behavioral ‘experiments’ such as exposure. Alexithymic 
patients with PD may have new emotional experiences 
during exposure sessions (e.g., by doing physical exercis-
es instead of avoiding activities because of their concerns 
about their physical health). This may encourage patients 
to challenge their dysfunctional beliefs and attitudes
(e.g., ‘What did I learn from this exposure?’, ‘What does 
it tell me about my fears?’), which may ultimately lead to 
a reduction in symptoms of anxiety.
 As an additional result, the presence of comorbid axis 
I disorders predicted posttreatment response as mea-
sured by the CGI. In earlier studies of PD, comorbidity 
with axis I disorders was also identified as one of a num-
ber of risk factors for poor treatment outcome  [51] . How-
ever, over the follow-up period, our patients with and 
without comorbid axis I disorders benefited comparably 
from the group therapy program. This is consistent with 
previous follow-up studies showing that group CBT tar-
geting PD and agoraphobia is beneficial for patients both 
with and without comorbid conditions  [52] .
 A further main finding was the significant decrease in 
TAS-20 total scores over time, and particularly in TAS-20 
factors 1 and 2, even after controlling for depression. It is 
of note that the treatment protocol used in this study was 
clearly designed to reduce symptoms of PD and not alex-
ithymia. Why then did alexithymia improve during this 
relatively short period of time? One reason could be that 
all patients received CBT including therapist-guided in 
vivo exposure with an emphasis on anxiety management 
 [32] . By means of therapeutically induced anxiety states 
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during exposure, patients were trained to cope with neg-
ative emotions and cognitions, and with unpleasant bodi-
ly sensations due to physiological reactivity. This ap-
proach may have helped them to improve their skills of 
emotion regulation, including their ability to identify 
and describe their own feelings. Another possible expla-
nation is related to the group setting: patients were en-
couraged to describe their feelings, e.g., anticipation anx-
iety, to each other and to the therapists, and to report on 
the results of their homework assignments, which in-
volved detailed self-observations of various feelings  [31] . 
A study of postmyocardial patients also found persistent 
reductions in alexithymia scores following group therapy 
 [53] . Interestingly, the therapeutic interventions used in 
this study were similar to our treatment approach in that 
both protocols emphasized paying attention to and de-
scribing one’s feelings, employed progressive muscle re-
laxation, and required practicing the techniques outside 
of the group session.
 Other elements of the group therapy program may 
also have led to reductions in alexithymic characteristics. 
By learning and practicing progressive muscle relaxation, 
including imagining a calm and comfortable place, and 
talking about their experiences to other group partici-
pants, alexithymic patients may have developed an in-
creased awareness of the relation between their physio-
logical arousal and emotions. This may have improved 
their ability to differentiate and regulate their affects by 
using psychological strategies, such as using imagination 
and communicating feelings to others. Friedlander et al. 
 [54]  reported that alexithymic individuals were no differ-
ent from nonalexithymics in their ability to relax physi-
ologically and subjectively during relaxation exercises. 
This supports our clinical observation that alexithymic 
patients are able to use relaxation as an affect regulation 
strategy, if they receive clear therapeutic guidance and 
instructions. Also psychoeducation about different com-
ponents of anxiety (cognitive, somatic, emotional, and 
behavioral) and the training of a differentiation between 
these components during exposure may have contributed 
to the improved ability to identify and describe feelings.
 However, because we did not include a control group, 
our data do not make it possible to draw any firm causal 
conclusions regarding our patients’ improvements in 
alexithymia. Therefore, and given that so far only few 
studies examined the effect of psychotherapeutic ap-
proaches other than CBT on alexithymia  [55–57] , con-
trolled studies are needed to establish the degree to which 
alexithymia can be modified by different psychothera-
peutic interventions.
 On the one hand, the significant reduction of TAS-20 
scores demonstrated a lack of absolute stability of alexi-
thymia. The high test-retest correlations, which were 
comparable to those of several previous longitudinal 
studies of alexithymia in other mental disorders [e.g.,  26, 
58 ], however, indicated the relative stability of alexi-
thymia. Thus, our findings are in line with the view that 
alexithymia should not be considered as either a trait or 
a state phenomenon but as a complex manifestation that 
includes both trait and state components [for a detailed 
discussion of the temporal stability of alexithymia, see 
 25 ].
 In addition to the lack of a control group, some other 
important limitations of this study should be addressed. 
First, several factors may affect the generalizability of our 
results: all patients were recruited from a specialized CBT 
outpatient unit, were treated in groups, and had, on aver-
age, only moderate levels of PD. Moreover, the mean 
TAS-20 total score of 50.0 ( 8 9.6) in our sample, although 
comparable to that reported by Bankier et al.  [4] , was con-
siderably lower than those reported from other PD stud-
ies which had found TAS-20 total scores of 57.5 ( 8 15.3) 
 [10] and 61.3 ( 8 8.0)  [11] . Thus, our results may have been 
different, had we examined PD patients with higher levels 
of alexithymia. Second, it cannot be ruled out that with a 
larger sample size, we might have detected a significant 
relationship between alexithymia and CBGT outcome. A 
third limitation is that concomitant medication and in-
dividual psychotherapy (prior to CBGT and during the 
naturalistic follow-up) may have had a significant impact 
on therapy outcome. It is possible, for example, that indi-
vidual psychotherapy has contributed to the reduction in 
PD symptomatology and the features of alexithymia ‘dif-
ficulty identifying feelings’ and ‘difficulty describing 
feelings’. However, in order to reduce the potentially con-
founding effect of additional individual psychotherapy, 
all patients who had psychotherapeutic treatment had to 
discontinue it before group therapy started.
 Furthermore, we did not assess axis II comorbidity; 
therefore, the possible influence of comorbid personality 
disorders on treatment outcome could not be examined. 
Finally, the self-report nature of the TAS-20 is an impor-
tant limitation. It is probably difficult for alexithymic pa-
tients to accurately rate their deficits  [59] . Bagby et al.  [60] 
recently reported on the reliability and validity of the To-
ronto Structured Interview for Alexithymia (TSIA), 
which is the first comprehensive structured interview 
with a specific focus on alexithymia. It includes specific 
prompts and probes, and may thus provide a more valid 
assessment of alexithymia. The German version of the 
 Rufer /Albrecht /Zaum /Schnyder /
Mueller-Pfeiffer /Hand /Schmidt 
Psychopathology 2010;43:170–179178
TSIA was recently evaluated  [69] . It might be promising 
to use such a clinician-rated instrument in future studies 
to explore more in-depth the potential impact of alexi-
thymia on psychotherapy outcome.
 In conclusion, our results are encouraging for cogni-
tive-behavioral therapists working with patients with 
alexithymia who suffer from PD: CBGT outcome does 
not appear to be negatively affected by alexithymia, and 
some alexithymic characteristics may even be reduced 
following CBGT. Future controlled studies should exam-
ine the degree to which alexithymia can be modified by 
different psychotherapeutic interventions.
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